FIG A3.

Best % change from baseline in 26 patients with evaluable measurements (n = 33 patient cohort). This plot excludes 5 unevaluable patients, 1 patient with multiple myeloma who had a minimal response, and 1 patient with pancreatic adenocarcinoma who was classified as having progressive disease but for whom complete data for target lesions were not available. (*) New lesions. Adeno, adenocarcinoma; ca, carcinoma; GYN, gynecologic; intra cholangio, intrahepatic cholangiocarcinoma; PD, progressive disease; PR, partial response; SD, stable disease.